Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?
Spinello Antinori, Cecilia Bonazzetti, G. Gubertini, Amedeo Capetti, Cristina Pagani, Valentina Morena, Sara Giordana Rimoldi, Laura Galimberti, Piercarlo Sarzi‐Puttini, Anna Lisa Ridolfo
Topics & Concepts
TocilizumabCytokine stormMedicinePneumoniaCoronavirus disease 2019 (COVID-19)Interleukin 6Cytokine release syndrome2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunologyCytokineVirologyInternal medicineOutbreakRheumatoid arthritisInfectious disease (medical specialty)DiseaseLong-Term Effects of COVID-19Autoimmune and Inflammatory Disorders ResearchCOVID-19 Clinical Research Studies